Europe Radiopharmaceuticals Market to Grow at a CAGR of 8.5% to reach US$ 3,442.11 million by 2028 Million from 2021 to 2028

Europe Radiopharmaceuticals Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine), Application (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Imaging Centers, Academic and Research Centers, and Others)

  • Report Code : TIPRE00025879
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 157
Buy Now

The Europe radiopharmaceuticals market is expected to grow from US$ 1,940.54 million in 2021 to US$ 3,442.11 million by 2028; it is estimated to grow at a CAGR of 8.5% from 2021 to 2028.



The UK, Germany, France, Italy, and Spain are major economies in Europe. Rising advancements in nuclear imaging techniques is expected to fuel the market growth. The use of nuclear medicine procedures is expanding rapidly, as PET and SPECT continue to improve the accuracy of detection, localization, and characterization of disease. PET and SPECT are among the nuclear medicine radiology modalities employed in clinical settings. As per the Society of Nuclear Medicine, every year, millions of nuclear medicine procedures are performed with radiopharmaceuticals and imaging instruments to diagnose disease and deliver targeted treatments in the countries across the region. These techniques have also been adopted in immunology, infection, gastroenterology, cardiology, oncology, neurology, and psychiatry, among other fields, for diagnosis and other applications. Advanced nuclear medicines and modern imaging equipment are assisting doctors in diagnosing diseases in a better manner and in less time. Continuous development of new radiopharmaceuticals for the PET/CT and SPECT/CT platforms, which are used in novel clinical applications such as neurology and orthopedics, along with the increasing accuracy of different tumor staging methods, are further contributing to the market growth. In September 2020, Curium launched Detectnet, a positron emission tomography (PET) agent, indicated for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult patients. Thus, the technological advancements for improving the quality and efficacy of nuclear imaging techniques are favoring the Europe radiopharmaceuticals market growth.

In case of COVID-19, Europe is highly affected especially France and Russia. The COVID-19 pandemic has profoundly changed hospital activities, including NM practice across Europe. A literature search on PubMed was performed covering COVID-19 studies published up until January 2021. As per the findings, the pandemic strongly challenged NM departments, and a reduction in the workforce has been experienced in every center in Europe. NM departments introduced restriction measures to limit COVID-19 transmission, including rescheduling of non-high-priority procedures. Also, some of the departments experienced a delay in radiopharmaceuticals supply or technical assistance due to COVID-19. As a result, the pandemic resulted in a significant reduction of diagnostic and therapeutic NM procedures and a reduced level of care for patients affected by diseases other than COVID-19, such as cancer or acute cardiovascular disease. The pandemic influenced workflows in a substantial proportion of NM departments. New findings supporting COVID-19 diagnosis are expected to accelerate the growth of radiopharmaceuticals in the region. For instance, as per the research study by Chentao Jin et al., published in the European Journal of Nuclear Medicine and Molecular Imaging in May 2021, positron emission tomography (PET) is expected to offer pathophysiological alternations of COVID-19 and facilitate the clinical management of patients. With the role of PET in the COVID-19, the research studies can also pave the way in combating other epidemics in the future.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe radiopharmaceuticals market. The Europe radiopharmaceuticals market is expected to grow at a good CAGR during the forecast period.
Europe radiopharmaceuticals market

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Europe Radiopharmaceuticals Market Segmentation      

Europe Radiopharmaceuticals Market – By Type

  • Diagnostic Nuclear Medicine
    • SPECT
    • PET
  • Therapeutic Nuclear Medicine
    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy Isotopes

Europe Radiopharmaceuticals Market – By Application

  • Oncology
  • Cardiology
  • Neurology
  • Others

Europe Radiopharmaceuticals Market – By End User

  • Hospitals
  • Imaging Centers
  • Academic and Research Centers
  • Others

Europe Radiopharmaceuticals Market, by Country

  • Germany
  • France
  • UK 
  • Italy
  • Spain
  • Rest of Europe

Europe Radiopharmaceuticals Market -Companies Mentioned

  • Advanced Accelerator Applications
  • Bayer AG
  • Bracco Imaging S.p.A 
  • Cardinal Health Inc
  • Curium
  • ECZACIBAŞI MONROL NUCLEAR PRODUCTS CO.
  • GENERAL ELECTRIC
  • Lantheus Medical Imaging, Inc.
  • Nordion
  • NTP RADIOISOTOPES 
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

  1. Advanced Accelerator Applications
  2. Bayer AG
  3. Bracco Imaging S.p.A
  4. Cardinal Health Inc
  5. Curium
  6. ECZACIBA?I MONROL NUCLEAR PRODUCTS CO.
  7. GENERAL ELECTRIC
  8. Lantheus Medical Imaging, Inc.
  9. Nordion
  10. NTP RADIOISOTOPES  

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Europe Radiopharmaceuticals Market